Dyslipidemia in women with polycystic ovary syndrome: incidence, pattern and predictors
Carregando...
Citações na Scopus
42
Tipo de produção
article
Data de publicação
2011
Título da Revista
ISSN da Revista
Título do Volume
Editora
INFORMA HEALTHCARE
Autores
BARCELLOS, Cristiano R. G.
CURI, Daniela D. G.
Citação
GYNECOLOGICAL ENDOCRINOLOGY, v.27, n.10, p.814-819, 2011
Resumo
One hundred forty-two women with polycystic ovary syndrome (PCOS) with an average body mass index (BMI) of 29.1 kg/m(2) and average age of 25.12 years were studied. By BMI, 30.2% were normal, 38.0% were overweight and 31.6% were obese. Thirty-one eumenorrheic women matched for BMI and age, with no evidence of hyperandrogenism, were recruited as controls. The incidence of dyslipidemia in the PCOS group was twice that of the Control group (76.1% versus 32.25%). The most frequent abnormalities were low high-density lipoprotein cholesterol (HDL-C; 57.6%) and high triglyceride (TG) (28.3%). HDL-C was significantly lower in all subgroups of women with PCOS when compared to the subgroups of normal women. No significant differences were seen in the total cholesterol (p = 0.307), low-density lipoprotein cholesterol (LDL-C; p = 0.283) and TGs (p = 0.113) levels among the subgroups. An independent effect on HDL-C was detected for glucose (p = 0.004) and fasting insulin (p = 0.01); on TG for age (p = 0.003) and homeostatic model assessment insulin resistance (p = 0.03) and on total cholesterol and LDL-C for age (p = 0.02 and p = 0.033, respectively). In conclusion, dyslipidemia is common in women with PCOS, mainly due to low HDL-C levels. BMI has a significant impact on this abnormality.
Palavras-chave
Polycystic ovary syndrome, dyslipidemia, insulin resistance, cardiovascular risk
Referências
- Pirwany IR, 2001, CLIN ENDOCRINOL, V54, P447, DOI 10.1046/j.1365-2265.2001.01228.x
- Cibula D, 2000, HUM REPROD, V15, P785, DOI 10.1093/humrep/15.4.785
- Strowitzki T, 2002, GYNECOL ENDOCRINOL, V16, P45, DOI 10.1080/713602996
- Yilmaz M, 2005, GYNECOL ENDOCRINOL, V20, P258, DOI 10.1080/09513590400027265
- WILSON PWF, 1988, ARTERIOSCLEROSIS, V8, P737
- FERRIMAN D, 1961, J CLIN ENDOCR METAB, V21, P1440
- Raal FJ, 2009, METAB SYNDR RELAT D, V7, P83, DOI 10.1089/met.2008.0079
- Legro RS, 1999, FERTIL STERIL, V72, P990, DOI 10.1016/S0015-0282(99)00401-X
- Dunaif A, 1997, ENDOCR REV, V18, P774, DOI 10.1210/er.18.6.774
- HOLTE J, 1994, CLIN ENDOCRINOL, V41, P463, DOI 10.1111/j.1365-2265.1994.tb02577.x
- Legro RS, 2001, AM J MED, V111, P607, DOI 10.1016/S0002-9343(01)00948-2
- [Anonymous], 2002, CIRCULATION, V106, P3143
- Knochenhauer ES, 1998, J CLIN ENDOCR METAB, V83, P3078, DOI 10.1210/jc.83.9.3078
- Assmann G, 1996, ATHEROSCLEROSIS, V124, pS11, DOI 10.1016/S0021-9150(96)90501-8
- Legro RS, 2003, ENDOCR REV, V24, P302, DOI 10.1210/er.2003-0004
- AZZIZ R, 2006, J CLIN ENDOCR METAB, V91, P37
- Barcellos CRG, 2007, ARQ BRAS ENDOCRINOL, V51, P601, DOI 10.1590/S0004-27302007000400015
- Carmina E, 2003, HUM REPROD, V18, P2289, DOI 10.1093/humrep/deg440
- CONWAY RS, 1992, CLIN ENDOCRINOL OXF, V37, P119
- DEAN JA, 2000, EPI INFO 2000 DATABA
- DIAMANTIKANDARA.E, 2007, TRENDS MOL ENDOCRINO, V18, P208
- Fauser BCJM, 2004, HUM REPROD, V19, P41, DOI 10.1093/humrep/deh098
- FRIEDEWA.WT, 1972, CLIN CHEM, V18, P499
- HEISS G, 1980, CIRCULATION, V61, P302
- Marcondes JAM, 2007, ARQ BRAS ENDOCRINOL, V51, P972, DOI 10.1590/S0004-27302007000600012
- MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
- MATTSSON LA, 1984, FERTIL STERIL, V42, P579
- Monrad RN, 2009, J CLIN ENDOCR METAB, V94, P2394, DOI 10.1210/jc.2008-1858
- Rose PG, 1996, NEW ENGL J MED, V335, P640, DOI 10.1056/NEJM199608293350907
- RUSSELL JC, 1993, ATHEROSCLEROSIS, V100, P113, DOI 10.1016/0021-9150(93)90073-4
- SLOWINSKASRZEDNICKA J, 1991, J ENDOCRINOL INVEST, V14, P569
- WILD RA, 1985, J CLIN ENDOCR METAB, V61, P946
- Zawadzki J, 1992, POLYCYSTIC OVARY SYN, P377